CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Tosedostatdrug
Likely dose
Tosedostat 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02452346
NCT02452346Phase 2Completed
CompareCT.gov

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy

Weill Medical College of Cornell University·interventional·Posted May 22, 2015·Updated Jun 12, 2018

In Brief

A Phase 2 clinical trial evaluating Tosedostat for Myelodysplastic Syndrome. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Study WCMC IST-CTI-MDS evaluates the safety and tolerability of tosedostat in adult patients with pathologically confirmed MDS (\< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification after failure of hypomethylating agent-based therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndrome
CountriesUnited States
CollaboratorsCTI BioPharma

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 22, 2015
Enrollment StartMar 20, 2015
Primary CompletionOct 25, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.1 years ago

Interventions

Tosedostatdrug

120 mg PO once daily continuously for each 28 day treatment cycle